We are live.
Live.
We are live now. Good afternoon. Welcome to day two of the Wolfe Healthcare Conference. My name is Mike Polark, medical device analyst here at Wolfe Research. Pleased to be joined in this session by Beta Bionics. From the company, we have CFO Stephen Feider and Head of Investor Relations, Blake Beber. Stephen and Blake, thanks for being here.
Nice to be here.
I have a set of questions. Maybe pass it to the team to set the stage, update us on the roadmap ahead, and maybe do a live product demo.
Yeah, for those listening to the call here on the recording, you are not going to be able to see the Mint demonstration, but we are going to do a Mint demo. I presume you have not seen one before, Mike Polark?
In 3D, no. Correct.
Okay, awesome. Well, this. In real life, you have not seen one. Awesome. We are hugely enthusiastic about Mint and the outlook for it. There are patients today, internal employees, including our CEO, who are wearing the device. The reviews on that are rave from healthcare providers who are familiar with the design of the product and the specifications of it. Hugely excited. We are enthusiastic as ever about the outlook. Before I do the demo, I will just say Mint was designed with the. Every design decision of Mint was designed with the user's experience in mind. Diabetes, big burden to live with, and we wanted to make the Mint, or have the Mint technology take on as much of that burden as possible, removing burden from the user.
I will start with just the specifications of the product, and then I will explain kind of what the components. This is the same size and the same weight, same insulin capacity, same wear time as the current market-leading patch pump product. It, again, on body, it looks very, very similar besides maybe just a slightly different color. There is no recharging associated with this device. I will explain why that is such an advantage in just a moment. Mint is made up of two parts. Mint has a Mint controller. This is where all the intelligence of the product lives. You do not recharge this, but you get one of these and you replace it every two years, and no recharging. Then there is the Mints, which are the disposable portion of the device. You use this and you throw this away every three days.
This is what you fill with insulin. This is where the batteries are. This is where the cannula lives and the adhesive. What I've done for this demonstration, one notable thing about Well, so this one I just took off my body. Sorry, I took off the durable component by breaking the Or I should say the reusable component, the Mint controller, by breaking the Mint, and this would go in the trash. Okay. That's done. Now, the next part of the process is you would fill the Mint with insulin. In this case, it's saline. I do not have diabetes, so I put sterile saline in. That is not a miserable process, but it takes a bit of time, so I've chosen to fill this one in advance.
Very important statement here about that fill process is that's no different than any other pump on the market or pump being considered. At the moment, there are no pumps and patch pumps that ship with insulin already pre-filled. May there be a day where that becomes the case, I suppose, but it's a very challenging regulatory path for that to be the case, and you'd have to fill them with a variety of different insulins, like whatever is on formulary, et cetera. I do not see a near-term solution to solve that problem. All right, so here's the Mint. That's now full of sterile saline. And I'll take my Mint controller and slide the devices together. And what you'll hear now is some beeping. Hear the beeps, Mike?
Yep.
It's prime time. What I call this is it's priming. It's the same thing that every pump would do. What it's doing is it's pushing air out of the cartridge so that it knows, like, with the first time that it wants to inject insulin, it actually will. Just take a moment. Now we'll hear one long beep, and that means that it's ready for me to deploy. I will now Ooh, this might be an issue. Okay, I'll take off this part of my shirt here. I'm wearing a Libre CGM, so that's what it's integrating with.
Libre three?
Libre three, yeah. It also will integrate with Dexcom, but I am wearing Libre today. Remove the adhesive. Very straightforward. Put it on there. Then I will remove this needle guard, which is the orange piece, and then I deploy the cannula by pushing in the button. That one I did not feel at all. I have now put on 50 of these things probably, through various demonstrations, and I hardly ever do feel them.
Occasionally, I will feel one, but I think the notable thing about the pain of insertion or the comfort of our device is we ran a study with 30 users of the current incumbent patch pump, and so that is what they are currently using, and we had them try on Mint and that product, so side by side, and we asked them to rank the pain of insertion, and every single person ranked the pain of insertion for Mint as less painful than the incumbent or our competitor. A couple other things I want to share. The most notable one is, what did you not see me do there? The first thing is you did not see me interact with my phone at all.
With other products, in particular the leading product, there is constant interaction with the phone to unpair the device that you currently have paired, because if there is a Bluetooth connection to the device that you throw away, to pair the new one, and then the actual insertion process is done, or it is conducted through the phone. The back and forth in and out of your phone, we have eliminated that step. What you also did not see is any recharging or charging associated with this. I will remind you, the reusable portion, the Mint controller, contains no batteries. That got powered on once it was connected to the Mint, which is where the batteries live. Two notable points there. If you cannot hear it in my voice, we are again hugely enthusiastic of this.
This will run the same algorithm as iLet, and yeah, there are already people wearing them in the real world today.
Great demo. Is this the box? Describe this box, and is this a starter kit?
Yeah, this is the starter kit, and it contains the controller.
Yeah.
The user guide, and then 10 Mints. So two boxes of five Mints. Every month, a user will get a box that looks very much like this, but does not contain the Mint controller. It will just contain 10 Mints, or some patients will need more than that, so they may get a box, a third box to make 15.
Yeah.
Yeah. If you use more than, say, 200 units every three days, you may need more than 10.
Yep.
Yeah. That is it. That is the demo.
Great demo.
Thank you.
I will get into Mint. 2027 sets up to be a really exciting year for your company. I see kind of three vectors of growth, your people, your product, and your algorithm. I want to start on the people. I think this year, it has been described, you have expanded the sales force by approximately 30%, if I have the math right, added 20 territories up from the base. Yeah, adding 20 territories is about 30% growth year on year. You did this into a fourth quarter that is semi-bizarre, folks waiting for Mint. What are they doing now? All these extra folks that you've hired to sell your product, it's not a perfect 90 days to go hard soon, but what are they doing this quarter? Tell me how they're prepping the market for Mint.
They have territories that are their respective areas of the country, and they're selling iLet. We had a public timeline that we had communicated on Mint's commercial expectation. Internally, of course, we had a very different expectation. We wanted to set an expectation to the market that, in the range of possibilities, was maybe a worst-case outcome for us. We had plans, of course, to launch Mint much earlier than Q4 2027, which is where we started 2026 with the guidance.
Yep.
Our company's belief structure, and certainly mine, is that the right thing to do for Beta Bionics was expand the sales force and have the size of a sales force presence for a Mint launch, roughly six to 12 months before we actually were launching Mint. We did expand the sales force earlier than we would've otherwise if Mint was coming, say, two years later. But today, it's not as if they're sitting around not selling any product, but they also aren't prepping the market really for Mint, because we need to sell iLet. We expect that users of our new patients on iLet are going to prefer to transition to Mint, but iLet's benefits and its value proposition are still extremely strong.
We are selling iLet even despite this new product on the horizon that is a form factor most patients are going to prefer.
Okay. This fourth quarter is iLet-
iLet
knowing there may be some decisions to wait.
Yeah, absolutely. You will notice, I mean, I am talking to you guys about Mint today because you are a different audience, but you are not going to see us really, I mean, with some exceptions, put out dramatic marketing pieces or shift much of our focus towards selling the benefits of Mint. When it is commercially ready to be launched, we will pivot to that, but not much in advance.
How about on just to close the thread on territory expansion, how did you do that? I mean, was it depth? Was it breadth? You splitting successful territories? What was the approach to adding those heads, and what do you expect to be the return of those changes?
The territory dividing is very mathematical. In our case, we use insulin pump prescribing patterns or insulin pump prescribing history, rapid-acting insulin prescription volume, and CGM prescription volume, and we can then quantify an opportunity for each zip code in the country. We do that, and then we use a map-based tool to map out what is the most effective way to cover that dirt with, in our case, the 80 territory directional number. That is actually extremely straightforward. That is the answer.
Did you have full national coverage before this, or no, this fills in holes that exist?
Yeah, we did have national coverage, but the reality of where a sales rep was living in certain geographies, it was unrealistic for that particular sales rep to cover certain parts of the country. New York City might not be a perfect example of this, which is where we are sitting right now, but something like a city of Houston had one sales territory. It was like the whole city of Houston, but that is actually not realistic for them to cover. You end up driving too much to realistically cover that area, and there are too many accounts. That territory, for example, was divided into two, and now there is a north and a south Houston.
Okay. When was this expansion this year completed? Middle of the year?
Yeah, in the late second quarter.
Okay.
Yeah.
And so far, so good?
Yeah. I mean, look, our sales and marketing spend as a percentage of revenue is over 70%, so it is definitionally not good. But the point is that we are making, we have made these investments under the full grounds knowing that we have a very clear path to launching a next-generation product, and we want to have our full commercial presence in order to do that. We also know that it is going to take us time to develop these relationships with endos, and that is happening.
The demo, like you just did for us, is that something a rep could be doing for a doctor right now?
Not right now, because we don't want them selling Mint.
Okay.
We want the-
You are FDA approved, so you could-
We could.
You could be doing it.
Oh, absolutely.
You have a quarter, a year to-
We are launching Mint to-
You have financial goals to meet in the short run.
Right. I don't think we don't expect it's going to be. There's a lot of spreading the word on Mint we don't perceive to be very problematic once it's the time for us to do that. But for the time being, yeah, we want our sales reps focused on selling iLet.
Last one on this, then we'll get to Mint and 3D Intelligence. Just constructing that fourth quarter guidance deferral, how did you go about doing it? From September, it was $10 million, 45 days later, it's $8.5 million. I guess just financially, the process to frame that, how did you come up with that estimate?
We get approval for Mint mid-September, and we knew there would be some, what I call Osborne effect, which is deferral of current product for what is in the eyes of the consumer perceived as a premium product. We knew there would be some element of that, so I chose $10 million because I thought it was the worst case. To be honest, I didn't have much data. All I had was some user survey data to indicate that people definitely were going to prefer Mint, but there was nothing more to it than just what I kind of thought was a low case for Q4.
We then had six weeks before the earnings call from the day we got clearance to when the Q3 earnings call was, and it turned out there was still a huge appetite for iLet, even despite many people asking for Mint and the awareness of Mint out there. We reduced what I considered the worst case.
Okay. Let's shift gears to Mint. Great demo. You got to make a lot of those to tap into this market. Talk to me about manufacturing. What's ready today? What's in the process of being ready very soon? Maybe, you have great growth ambitions from this product, kind of the roadmap for 2027 and 2028 from a scaling of disposables perspective.
This is the highest priority operational project at Beta Bionics now. We have a lot of confidence that whatever we make in 2027, we will sell. By the way, it's kind of a weird structure for companies to say what's considered highest priority and least highest priority. There's kind of resourced projects and there's non-resourced, but you just can't underestimate how important, in our case, now getting Mint to a manufacturing scale where we can take advantage of what we believe the patient demand will be. That is as high of a priority as it could get for a company like us. What we've promised is that we'll make at least 1.5 million Mints in calendar year 2027. That's a minimum number, so of course, we have internal goals to exceed that, but that, again, that is a minimum.
Today, we're building them at our manufacturing lines in Irvine in our fully functioning clean room. It's operational. Is it to the level that we need it to be? Is this exact line, is it to the level we need it to be? No. Is this exact line and how it's operating and the humans involved in each of the steps what we intend for even those lines to look like in six months? No. But point is, we're like in a crawl, walk, run mode here, and I feel really good.
The controller, is that same facility? Are you already stockpiling those?
Yeah.
Okay.
Same facility, non-clean room, and it is mostly assembled in a manual environment. But the cost profile on that, of course, it is important for us to bring down cost to as low as we possibly can. But the cost profile on that is less important because relative to, say, 240 Mints that a user would use over two years, you use only one controller.
Yep.
The reliability is most important there.
Just talk to me about your Mint is FDA approved. You are making it. This is 1/1, this is 2/15, this is 3/31. It has been described as a 1Q launch.
Yeah.
I want to understand kind of what you are really prepping for.
I will not share more detail other than we are expecting a meaningful amount of revenue in the first quarter from Mint. But specifically, like where within the quarter that falls, I do not want to communicate.
Okay. Let us talk about Mint contracting. Is that a hurdle to clear or it is going to be pharmacy only?
Your pharmacy mix goes up a lot as you move into Mint mix. But the contracts are ready to go, kind of comparable to. Do you ride the tails of the iLet pharmacy contracts, or you are recutting this for Mint, and just the level? Is that complete? Is that in process? If it is in process, what does that coverage process look like over the next year?
I'll start by setting the stage. We expect 40% of all patients in the U.S. to be able to purchase Mint with their pharmacy benefit on the day of launch. We expect that to grow to 50% by the end of our first year on the market. By contrast to our patch pump competitor, the market leader, they're somewhere. It depends on which data you look at, but it's not 100%. It's somewhere between, what I believe is between 70% and 100%. So a wide range, but that's where our aspirations are. The effort to do that is first you need to win PBM agreements, in which case we've won those already for iLet, so it does make it substantially easier for us to win them for Mint, and that is, of course, already in process.
In many cases, this is just an amendment to an existing contract. You have underlying health plan decisions, which similarly, we've already demonstrated an ability to win for iLet, but we'll have to do the same thing for Mint. What is going to be the longer pull or the longest pull for Mint pharmacy coverage that we actually have a better pitch for with Mint than iLet that I'll get to in a second, is state Medicaid plans, which are really important for pediatrics for reasons I could get into. The reason, by the way, that now we have a better tool to sell to state Medicaid and for pharmacy reimbursement is that with iLet, the product is medically reimbursed as a default.
Every single payer that we've gone to, we've in essence been saying, "Hey, Mike, I see that you're covering this as a medical benefit, but we want you to cover it another way in pharmacy, and it's a different pricing structure. It's better for your patients." That's the pitch. With Mint, we go to them and say, "Hey, we have a next-generational technology. Here's the clinical outcomes on it. Here's what the patient demand is. If you don't cover it through your pharmacy benefit, your patients can't access it." It's a way different pitch. For that reason, our pharmacy outlook in terms of market access or reimbursement growth is much brighter than the iLet outlook.
The ambition for starts next year on Mint is something close to, but not quite 20,000. It's a significant number. iLet will be on top of that. That's net new starts. My question is your base. How do you anticipate your iLet base, which last year at the end of the year, we had 35,000. This year, we think it's in the zone of 50,000. How do you model those folks converting to Mint, and is there going to be a program? How are they offered that opportunity?
Well, let's start by saying that I do believe that most of our patients today, if they could have chosen Mint when they chose to start on iLet, they would have. I guess the key point in that statement is that they've already known that they were sacrificing the form factor of their preference to choose iLet for other reasons.
Yeah.
I don't expect, even if that remains true, that many patients of our existing install base would prefer to switch over to Mint. What I want to make sure I'm addressing any potential concern is, "Oh, geez, well, if they don't have enough Mints in 2027, will their existing install base just melt away?" But remember that these people have already had a patch pump alternative that they could have chosen, so I don't think that that will at all be true. Now, getting specifically to your question of how will we allocate demand, I think that of all people who start on Mint in 2027, roughly two-thirds of them will come from new patients, and one-third of them will be people who are transitioning from iLet to Mint.
Now, that doesn't mean that that one-third is going to be every single existing install base member who wants to transition to Mint, but it's our effort to make it possible for them. Now, those numbers get better, assuming we can make more.
Last one and we'll move on. In the interest of time, I need to get to 3D Intelligence. Conversions from the base, could it be folks going DME to pharmacy as part of that trade, or would you just model it primarily folks that are iLet in pharmacy can be Mint in pharmacy?
No, DME to pharmacy.
Okay.
That is the company's preference financially, which is why we will make that so.
Okay.
It is also advantageous for them as well, from an out-of-pocket cost perspective. Then just over the last two years, the amount of pharmacy coverage that we have built in that user base, despite them adopting a year ago or two years ago, there is certainly a number of them that will have pharmacy coverage.
Good. Let us go to 3D Intelligence. This was also part of the September update. It was new news. I found it interesting. I guess open-ended question, request for reminder. Why do this?
Why do 3D Intelligence?
What are you doing and why are you doing it?
One of the most important pieces of feedback that we get on our product, a sales objection, I guess you could call it, is certain endocrinologists and patients, they like automation, but they would prefer a lever to the automation. Meaning, you are driving in full self-driving, and they do not want one mode. They actually want a Mad Max mode, and they want a granny mode, and they want to potentially even be able to toggle between them.
So giving people automation and just saying that is very different than saying, "Hey, people do not like automation. They like getting under the hood, and they like toggling with all the settings." I do not believe that is true at all. But I think what is fair is that many patients would prefer a very, very easy-to-understand mechanism to express a little bit of control that changes their outcomes. We agreed.
We thought that feedback was fair. What we have done is we have taken our existing algorithm, and we have modified it to make an optimized version, which we think is going to reduce hypoglycemia but keep the same mean glucose, so same A1C. But then we have also offered a conservative mode, which you will trade off in that case a worse A1C, so higher A1C, but you will have less time below 54, or less time with hypoglycemia.
Really quickly, we were very confident based on our interactions with FDA and our breadth of experience in dealing with the agency that that clearance was going to come in the fourth quarter, hence why you heard us guide to it in September. It was just due to the nature of where the discussions were, and then we were wrong. That is embarrassing, of course. We have not missed a public promise like that.
This is the first time. The reason we were wrong is, candidly, we just got some questions kind of late in the game, which are all fair. It is totally the FDA's right to do that. I do not want to sound critical. We were unable to answer them within the 90-day time parameter, and the FDA politely asked us to withdraw it and resubmit it. I will say this, we then communicated on our earnings call that this was a near-term path for resubmission, and we have now resubmitted.
What needs to be approved? Original algorithm is still part of 3D. Now you have optimized and conservative, so there is three choices. Is it the two new versions that are being reviewed, or is it the whole three-choice concept? It is the-
The two.
The original algorithm is not subject to review.
Correct.
It's the two incremental.
Correct.
Okay.
Yeah.
This question has come to me, like, I did look into simulation, and I guess, you got a frontier algorithm through before. That's my word. I think you're living on the insulin pump algorithmic frontier.
Thanks.
That's a compliment.
Yeah, thank you.
Then you introduce a safer one and a slightly hotter one.
Why didn't it get through? Where are they asking questions, things that weren't well-framed?
No questions on the algorithms themselves, which I could get into why that is and where maybe the future of simulation might go for insulin pumps, or insulin pump algorithms, but we can get to that if we have time. But the questions were on validation of the simulator. We have to make a simulator, a homegrown bespoke simulator that is representative of a population with diabetes, and then convince the agency that our simulator actually does that. Now, I don't think they believe that we haven't done that, but the actual validation of it and the documentation to prove that was unsatisfactory, and that's where we were getting our questions.
Was this the simulator used to get the original algorithm through, or?
No. This is where I think simulation is really interesting, is that I don't think you're going to see simulation evolve to where Mike Polark starts a company, an insulin pump company, creates an algorithm using AI, puts together his own simulator, validates it, then gets an algorithm approved by the FDA as a totally new concept. That's not the case. I think the near-term path for that is extremely unlikely. What we're doing here is we're making safe modifications to existing cleared algorithms that we can run in side-by-sides comparisons. I think that's where simulation can evolve, is instead of running 18-month timelines to make a tweak to an algorithm, you just start looking at the real world, then you have assessed what you can do in simulation, then the tweak is convincingly safe.
That's where the FDA is evolving, I think in a great way, on the capabilities of simulation.
The update there was, has resubmitted, so appreciate that. You can launch that without this 3D, then once you get this, it's over the air.
3D is firmware-over-the-air upgrade to every Beta Bionics user at that time.
Yep.
That could be pre-Mint, in which case every Mint would have it, or if it is post-Mint, then every Mint would get it.
If you were not launching Mint this year, and it was only in 2027, let us say, and it was just going to be an iLet year, how would you frame the benefit from 3D Intelligence from a growth and starts perspective?
Underrated. Underrated. It is not obvious, I think, to the investor world how big of an impact having multiple modes to automation is. I think that when you do your doctor calls and healthcare provider calls, to the extent that you do, you would find that particular community actually is very positive on the future of automation, but again, they want to have some level of control. So, I think it addresses Tubeless is our number one sales objection. It just is. But this is number two in terms of importance. I think it has a way underappreciated impact on next year, Mint or not.
One more to wrap us. Type two. I find this interesting. You do not have a label. 30% of your starts are type two. The question to you is, and the trial is completed enrollment mid-2027, label enhancement is the expectation. What does that do for you?
Can market the data.
Okay.
I can't say anything more here about what it's doing for patients with type two, but we can market it.
Is the why now, because the type two question you've gotten for a couple years, and is the why now related in part to just Mint and the appeal of the patch hardware to that population, or no?
No, the why now was Sean and I were passionate that there was a way, because of the preponderance of evidence that we had had in the real world for people with type two, that there was a way to get that indication without running the massive clinical trial, the hugely expensive one. We couldn't really say that to you guys, because we didn't have a clear plan for it. The FDA, over extensive back and forth, they eventually agreed with us that, yes, this is safe, demonstrate it using this observational trial and your existing real-world data. We had always wanted a type 2 indication.
Yep.
It's just we had to be careful what we were saying, because we didn't want to tip our hand on this particular project. But now that it was agreed upon and the trial started, we started talking about it.
Will the 3D Intelligence apply to type two and all be kind of covered together? It's probably a dumb question, because I know-
It's not a dumb question at all. I'm not going to answer it. It's not exactly certain. We have not agreed perfectly with FDA on how that's going to work. There is a solution here that's elegant. There's a bunch of different ones. I just don't know the exact perfect elegant solution that we're going to market with.
Cool. Okay. We got to leave it there.
Thank you, Mike.
Blake, thanks for being here tonight.
Yes, of course.
Great demo.
Yeah, I appreciate it.
Thank you.